Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Telegram Messenger Ondersteuning voor Stoppen met Roken na een Hartaanval (TELEGRAM-MI)

4 november 2026 bijgewerkt door: Mikhail Kuznetsov, ITMO University

Effect van een gedragsinterventie afgeleverd via Telegram Messenger op stoppen met roken bij patiënten na een myocardinfarct: De TELEGRAM-MI gerandomiseerde gecontroleerde studie

This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).

Adult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:

  • INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.
  • CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.

The primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.

This study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.

Studie Overzicht

Gedetailleerde beschrijving

The TELEGRAM-MI trial is a multicenter, randomized, controlled, assessor-blinded superiority study testing a digital behavioral intervention for smoking cessation in post-myocardial infarction patients.

BACKGROUND: Smoking cessation is the most effective modifiable risk factor for reducing mortality after MI, yet long-term abstinence remains challenging due to limited sustained support. Digital interventions using popular messaging platforms offer a scalable solution to bridge the post-discharge support gap.

OBJECTIVES:

Primary: To determine if a 6-month Telegram chatbot intervention increases 30-day point prevalence abstinence rates at 6 months compared to standard care alone.

Secondary: To examine associations between baseline characteristics (nicotine dependence, motivation), engagement metrics, and cessation success; and to assess intervention acceptability.

METHODS: Approximately 142 participants will be recruited from inpatient cardiology departments. After providing informed consent, participants will be randomized 1:1 via the chatbot to either the intervention group (standard care plus 6-month behavioral support) or control group (standard care plus data collection only). The intervention incorporates evidence-based techniques including motivational messaging, cognitive-behavioral strategies, and relapse prevention protocols.

OUTCOMES: The primary outcome is biochemically unverified 30-day point prevalence abstinence at 6 months, assessed via blinded telephone interview with participant and relative verification. Secondary outcomes include various smoking behavior metrics collected through the chatbot platform.

ANALYSIS: Primary analysis will follow intention-to-treat principles, with missing data imputed as smoking. Statistical analyses will include chi-square tests for primary outcome and regression models for secondary outcomes.

POTENTIAL IMPACT: If effective, this intervention represents a readily implementable, low-cost strategy to enhance secondary prevention in cardiac patients.

Studietype

Ingrijpend

Inschrijving (Geschat)

142

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Mikhail A. Kuznetsov, MD
  • Telefoonnummer: +79170610352
  • E-mail: mihkuzn@gmail.com

Studie Contact Back-up

Studie Locaties

      • Ulyanovsk, Rusland
        • Werving
        • Ulyanovsk Regional Clinical Hospital
        • Contact:
          • Administration of Clinical Hospital
          • Telefoonnummer: +7 8422 32 32 71
          • E-mail: uokb@med.ulgov.ru
    • Ulyanovsk Oblast
      • Ulyanovsk, Ulyanovsk Oblast, Rusland, 432000
        • Nog niet aan het werven
        • Ulyanovsk Regional Clinical Hospital
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Mikhail A. Kuznetsov, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Willing and able to provide written informed consent.
  • Age 18 years or older.
  • Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI), enrolment occurring either during index hospitalization or within 1 month post-MI at an outpatient visit
  • Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.
  • Regular user of the Telegram messenger application (app installed on a personal smartphone).
  • Possession of a smartphone with internet access and a valid phone number.
  • Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.

Exclusion Criteria:

  • Smoking cessation more than 1 month prior to the index MI hospitalization.
  • Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual/hearing impairment, inability to read or respond to messages).
  • Inability to read and understand the Russian language fluently.
  • Comorbid condition with a life expectancy of less than 1 year.
  • Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.
  • Unwillingness or inability to provide contact details for a close relative for outcome verification.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Telegram Bot Intervention Group

Participants receive standard care PLUS the 6-month behavioral intervention delivered via the Telegram chatbot.

A 6-month behavioral intervention delivered via a Telegram chatbot. The intervention includes personalized daily motivational messages, cognitive-behavioral techniques for craving management, access to an SOS/craving support button, weekly check-ins, and relapse prevention protocols. Content is tailored based on user responses to questionnaires (Fagerström Test, Importance/Confidence scales) and engagement metrics.

Ander: Standard Care Control Group

Participants receive standard care only. They are connected to the Telegram bot but only complete baseline and follow-up surveys without receiving any active smoking cessation content.

Routine physician advice to quit smoking provided upon hospital discharge. This represents the current standard of care in the participating clinical centers.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
30-day point prevalence abstinence (PPA)
Tijdsspanne: 6 months

Proportion of participants who report abstinence from smoking for the past 30 days or more, verified by both participant self-report AND corroborating report from a close relative or cohabiting person during a telephone interview conducted by a blinded assessor. A positive outcome is recorded ONLY if both sources confirm abstinence. Participants with missing data (e.g., lost to follow-up) will be considered smokers in the primary analysis (intention-to-treat).

6 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
7-day point prevalence abstinence (7-day PPA)
Tijdsspanne: 1 month and 3 months

Proportion of participants who report abstinence from smoking for the past 7 days. Assessed via the Telegram bot.

1 month and 3 months
Change in cigarette consumption
Tijdsspanne: Baseline, 1 month, 3 months, and 6 months

Change from baseline in the self-reported number of cigarettes smoked per day. Assessed via the Telegram bot.

Baseline, 1 month, 3 months, and 6 months
Score on the Fagerström Test for Nicotine Dependence (FTND)
Tijdsspanne: Baseline and 6 months

Change in nicotine dependence measured by the FTND questionnaire (score range 0-10, higher scores indicate greater dependence). Assessed via the Telegram bot.

Baseline and 6 months
Motivation to quit (Importance and Confidence Scales)
Tijdsspanne: Baseline and 6 months

Scores on self-rated scales (0-10) for the importance of quitting and confidence in the ability to quit. Assessed via the Telegram bot.

Baseline and 6 months
Participant engagement with the Telegram bot
Tijdsspanne: 6 months

Composite measure of engagement (dose) including: proportion of completed weekly check-ins, proportion of opened messages, number of SOS/craving button uses, number of active weeks. Metrics are automatically logged by the bot.

6 months
Intervention acceptability and satisfaction
Tijdsspanne: 6 months

Total score on a custom acceptability and satisfaction questionnaire (5-12 items) completed by participants in the intervention group via the Telegram bot. Higher scores indicate higher satisfaction.

6 months
Time to first relapse
Tijdsspanne: 6 months

Number of days from randomization to the first self-reported relapse (lapse) event. Assessed via continuous monitoring through the bot's check-in system.

6 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Mikhail Kuznetsov, MD, Ulyanovsk Regional Clinical Hospital
  • Studie directeur: Dmitry Sergeev, PhD, ITMO University
  • Studie directeur: Artemiy Okhotin, MPH, ITMO University

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

27 juli 2026

Primaire voltooiing (Geschat)

27 april 2027

Studie voltooiing (Geschat)

1 augustus 2027

Studieregistratiedata

Eerst ingediend

13 november 2025

Eerst ingediend dat voldeed aan de QC-criteria

14 november 2025

Eerst geplaatst (Werkelijk)

17 november 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

All individual participant data collected during the trial, after de-identification, will be shared. This includes demographic data, smoking history, questionnaire responses (Fagerström Test, Importance/Confidence scales), intervention engagement metrics, and primary/secondary outcome data.

IPD-tijdsbestek voor delen

Beginning 12 months after main results publication and ending 5 years after publication. Data will be available for this period.

IPD-toegangscriteria voor delen

Data will be available to researchers who provide a methodologically sound research proposal approved by an independent review committee. Proposals should be directed to the corresponding author. Requestors will need to sign a data access agreement specifying the purpose of analysis, commitment to secure data handling, and agreement not to attempt re-identification of participants.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren